Severe Obesity Clinical Trial
— BIPASSOfficial title:
Prospective Multicentric Randomized Trial Comparing the Efficacy and Safety of Sleeve Gastrectomy With Transit Bipartition (SG+TB) Versus Roux-en-Y Gastric Bypass (RYGB)
Obesity is a major public health problem worldwide. Bariatric surgery has proved to be the most effective treatment of morbid obesity in terms of weight reduction and remission of co-morbid conditions during long-term follow-up. Sleeve Gastrectomy (SG) has become the most performed intervention either worldwide or in France, where SG represents more than 60% of bariatric interventions and 114,817 patients operated between 2013 and 2016. Maximum Excess weight loss (%EWL) after SG is obtained at one-year post surgery. Then it has been largely reported in the literature that patients could present mild, moderate or important (notably in the super obese patients) weight regain associated with comorbidity relapse motivating redo surgery. Like in revisional surgery, operating super-obese patient (BMI ≥50 kg/m2) is a challenge. It has been shown that achieving significant weight loss was more difficult in patients with a BMI ≥ 50 compared to lower BMIs.
Status | Recruiting |
Enrollment | 320 |
Est. completion date | July 2025 |
Est. primary completion date | July 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Patient who has benefited from a pluridisciplinary evaluation, with a favorable opinion for SG+TB or RYGB as a first intention procedure with BMI =40 kg/m2 or BMI = 35 kg/m2 associated with one co-morbidity which will be improved by surgery (according to HAS 2009 recommendation3) OR as a second intention procedure (revisional surgery) after failure of Sleeve gastrectomy (defined as insufficient weight loss at 18 months after surgery (EWL% <50), or as weight regain (+ 20%)). - Patient who had benefited from an Upper GI Endoscopy with biopsies to look for Helicobacter Pylori (HP) and a HP eradication. - Patient who understands and accepts the need for a long-term follow-up - Patient who agrees to be included in the study and who signs the informed consent form - Patient affiliated to a healthcare insurance plan Exclusion Criteria: - History of previous bariatric surgery, other than a Sleeve Gastrectomy - Patient with current BMI > 60 kg/m2 - Presence of a severe and evolutive life threatening pathology, unrelated to obesity - History of Chronic inflammatory bowel disease - Type 1 Diabetes - Pregnancy or desire to be pregnant during the study - Nursing woman - Presence of Pylori Helicobacter resistant to medical treatment - Presence of a non-healed gastro-duodenal ulcer or diagnosed less than 2 months previously - Severe esophagitis (grade C of Los Angeles classification) - Hiatal hernia - Patients with unstable psychiatric disorder, under supervision or guardianship - Patient who does not understand French/ is unable to give consent - Patient not affiliated to a French or European healthcare insurance - Patient who has already been included in a trial which has a conflict of interests with the present study - Patient incarcerated |
Country | Name | City | State |
---|---|---|---|
France | Hop Claude Huriez Chu Lille | Lille | |
France | CHU de Lyon | Lyon | |
France | CHU de Nantes | Nantes | |
France | CHU Orléans | Orléans | |
France | AP-HP Hôpital Bichat | Paris | |
France | AP-HP Hôpital Georges Pompidou | Paris | |
France | CHU de Poitiers | Poitiers | |
France | CHU de Nancy | Vandœuvre-lès-Nancy |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Lille | Ministry of Health, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Excess Weight Loss percentage (EWL%) | The Excess Weight Loss percentage (EWL%) calculated with the following formula: ((weight at 2 years visit - initial weight (kg)) / (initial weight - ideal weight)) X 100 Ideal weight defined as the weight corresponding to a BMI = 25 kg/m2. Initial weight defined as preoperative weight at V1. All weights are expressed in kg | at 2 years after surgery | |
Secondary | Change nutritional status assessment | Nutritional profil : Hemoglobin (g/l), albumin (g/l), prealbumin (g/l) | from baseline (before surgery) to 24 months after surgery | |
Secondary | Change in liver status assessment | Liver parameters ( ALT AST GGT Alkaline phosphatases, Total bilirubin, prothrombin time, urea, creatininemia concentration) | from baseline (before surgery) to 24 months after surgery | |
Secondary | Change in vitamins status assessment | vitamins profil (vitamin A B1, B6 B9, B12, C , D and E concentration) | from baseline (before surgery) to 24 months after surgery | |
Secondary | Change in mineral status assessment | Mineral profil ( ferritin, potassium, calcium,iron, transferrin, magnesium, selenium, zinc phophore concentration) | from baseline (before surgery) to 24 months after surgery | |
Secondary | 24-hour steatorrhea quantified at 6 months | 24-hour steatorrhea is assessed to evaluate denutrition, expressed in g of lipid/24hr | At 6 months | |
Secondary | Evolution of muscle mass assessed by bioelectrical impedance analysis | muscle mass is assessed to evaluate denutrition. | from baseline to 24 months after surgery | |
Secondary | Evolution of muscle mass assessed by grip strength test. | muscle mass is assessed to evaluate denutrition. | from baseline to 24 months after surgery | |
Secondary | Complications rate within 2 years according to Dindo-Clavien classification | complications rate is assessed to evaluate safety of the procedure | within 2 years | |
Secondary | Length of hospital stay defined as the number of days of hospitalization | length of hospital stay for the surgical procedure | up to 2 week | |
Secondary | Evolution from baseline to 24 months after surgery of HbA1c level, HDL, LDL and triglycerides | Evolution from baseline to 24 months after surgery of HbA1c level (expressed in %), fasting glycemia (expressed in mmol/l or g/l), HDL (expressed in mmol/l or g/l), LDL (expressed in mmol/l or g/l) and triglycerides (expressed in mmol/l) | from baseline to 24 months after surgery | |
Secondary | Evolution from baseline to 24 months of insulinoresistance defined by HOMA-IR calculated with fasting blood glucose and fasting insulinemia12 | assessment of insulinoresistance | from baseline to 24 months | |
Secondary | Change of the GIQLI score | This questionnaire consists of 36 items exploring 5 dimensions or subscales: symptoms, physical condition, emotions, social integration and the effect of any medical treatment. For each item, 5 responses will be proposed to patients and for each answer, a score is assigned, ranging from 0 to 4 (highest score = 144). A high score defines a more favorable health state | from baseline to 24 months after surgery | |
Secondary | Change of the SF36 scores | This questionnaire taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. | from baseline to 24 months after surgery | |
Secondary | Change in Sigstad questionnaire score (dumping syndrome). | The Sigstad questionnaire allows the identification and diagnosis of postoperative hypoglycemia: a score > 7 suggests a dumping and a score <4 suggests another diagnosis.
Complementary questions regarding timing of dumping (<30 min or >1h30) will be asked if Sigstad score >7. |
from baseline to 24 months after surgery | |
Secondary | Change of food choices and preferences assessed by the Leeds Food Preference Questionnaire (LFPQ) score. | The Leeds Food Preference Questionnaire provides measures of different components of food preference and food reward. Participants are presented with an array of pictures of individual food items common in the diet. Foods in the array are chosen by the experimenter from a validated database to be either predominantly high (>50% energy) or low (<20% energy) in fat but similar in familiarity, protein content, sweet or non-sweet taste and palatability. Outcome measured are explicit Liking, explicit wanting, implicit wanting and food choice.
Scores for explicit liking and explicit wanting range from 0-100 with a typical mean (±S.D.) of 60±18 Scores for Food Choice range from 0-48 and have a typical mean of 24±10 or for the appeal bias range from -48-48 with a typical mean of -5±15. Scores for Implicit Wanting typically range from -100-100 (due to RT there is no fixed min-max value) and have a typical mean of ±10±25 or for the appeal bias a typical mean of -10±30. |
from baseline to 24 months after surgery | |
Secondary | Change of physical activity assessed by the International Physical Activity Index (IPAQ) score. | The International Physical Activity Questionnaire assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives to estimate total physical activity in MET-min/week and time spent sitting. | from baseline to 24 months after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03690752 -
Adherence to Walking on an Alter G Anti-Gravity Treadmill
|
N/A | |
Active, not recruiting |
NCT02767505 -
Bypass Equipoise Sleeve Trial (BEST)
|
N/A | |
Recruiting |
NCT05786092 -
Impact of Telemonitoring on Metabolic Variables in Severe Obesity
|
N/A | |
Active, not recruiting |
NCT03249441 -
Compassion-Focused Therapy for People With Severe Obesity.
|
N/A | |
Terminated |
NCT04626232 -
Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients
|
N/A | |
Completed |
NCT02952963 -
Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass
|
Phase 4 | |
Active, not recruiting |
NCT02374632 -
Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass
|
Phase 4 | |
Active, not recruiting |
NCT04165694 -
Single Anastomosis Duodenal Ileal Bypass (SADI) for Sleeve Revision
|
N/A | |
Not yet recruiting |
NCT06162715 -
GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Feasibility Trial
|
Phase 2 | |
Completed |
NCT05409612 -
Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients
|
Phase 3 | |
Completed |
NCT03638895 -
Energy Expenditure From ECAL Indirect Calorimeter in a Multicomponent Weight Management Service
|
N/A | |
Not yet recruiting |
NCT05493592 -
Pigeon Peas (Cajanus Cajan) : a Natural Anti-inflammatory Facilitating Weight Loss in Obese Patients Returning to Sport?
|
N/A | |
Completed |
NCT02823561 -
Garcinia Mangostana Extracts in the Management of Weight Loss
|
Phase 4 | |
Completed |
NCT02340247 -
Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass
|
Phase 4 | |
Recruiting |
NCT02076880 -
SLEEVEDIAB To Explore the Early and Late Metabolic Effects of Sleeve Gastrectomy in Obese Patients
|
N/A | |
Completed |
NCT04042493 -
Connect for Health Pediatric Weight Management Program
|
N/A | |
Completed |
NCT04129801 -
Muscle Strength in Severe Obese Patients in the Postoperative of Bariatric Surgery
|
||
Completed |
NCT05341414 -
Trajectories of Resilience and Bariatric Surgery Outcomes
|
||
Recruiting |
NCT02710786 -
Comorbidity After Gastric Bypass
|
||
Recruiting |
NCT02409160 -
Sleep and Immune Response in Severe Obese Patients Undergoing Bariatric Surgery.
|
N/A |